Psoriasis | Unmet Need | Moderate to Severe Psoriasis | US/FR/GE/UK | 2024
With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis market has been a lucrative space for drug developers. In recent years, the dynamics of the psoriasis market have started to change, as the use of established TNF-α inhibitors as earlier-line agents has slowly shifted to the earlier use of other biologics (e.g., IL-17 inhibitors Cosentyx and Taltz, IL-23 inhibitors Tremfya and Skyrizi) and oral targeted therapies such as the PDE-4 inhibitor Otezla. Despite the availability of multiple treatment options, the already cluttered psoriasis market has witnessed the launch of the oral TYK2 inhibitor Sotyktu and the fourth-in-class IL-17 inhibitor Bimzelx, indicating that the substantial unmet need still remains in the psoriasis space. Novel agents are needed that can differentiate themselves on the attributes of efficacy, safety, convenient delivery, and the ability to treat a broad patient population.
QUESTIONS ANSWERED
- How do dermatologists rate current therapies’ performance on key treatment drivers and goals for moderate to severe psoriasis?
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities in moderate to severe psoriasis?
- What are the greatest unmet needs and most attractive opportunities in the treatment of moderate to severe psoriasis?
- What trade-offs across key clinical / nonclinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new drug for moderate to severe psoriasis?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European dermatologists fielded in December 2023
Key companies: AbbVie, Eli Lilly, UCB, Novartis, Amgen, Bristol Myers Squibb
Key drugs: Humira, Taltz, Bimzelx, Tremfya, Skyrizi, Otezla, Sotyktu
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
KEY FEATURE
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
